In this study, we observed that KIF2A expression was negatively correlated with EFS and OS in AML patients, possibly because: 1) KIF2A might enhance cell proliferation but inhibit cell apoptosis via regulating various signaling pathways such as MAPK/ERK and PI3K/AKT, therefore it accelerated disease progression and eventually reduced survival time of AML patients (4,7–10); and 2) KIF2A might cause resistance to chemotherapy and further impair treatment efficacy, thereby leading to decreased EFS and OS. This evidence concerns the gene KIF2A and acute myeloid leukemia.